Drug intelligence / Profile preview

metronidazole + penicillin + tobramycin

Development stage
Unknown
Lead developer
Sanofi
Modality
Small Molecules
Administration
Intravenous, Oral, Intramuscular, Inhalation, Ophthalmic, Topical
01

Overview

This is a combination of three antibiotics—metronidazole, penicillin, and tobramycin. Each component has a distinct mechanism of action and antimicrobial spectrum:

  • Metronidazole is a nitroimidazole antibiotic effective against anaerobic bacteria and certain protozoa. It works by disrupting DNA synthesis in susceptible organisms, leading to cell death.
  • Penicillin refers to the class of beta-lactam antibiotics that inhibit bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), resulting in bacterial lysis.
  • Tobramycin is an aminoglycoside antibiotic that binds irreversibly to the 30S subunit of bacterial ribosomes, inhibiting protein synthesis and causing cell death. It is particularly active against Gram-negative bacteria such as Pseudomonas aeruginosa.

This combination would provide broad-spectrum coverage against aerobic Gram-positive (penicillins), Gram-negative (tobramycin), and anaerobic organisms (metronidazole). Such combinations are sometimes used empirically for severe mixed infections or intra-abdominal infections where polymicrobial etiology is suspected.

02

Targets

Beyond the preview

Go deeper on metronidazole + penicillin + tobramycin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on metronidazole + penicillin + tobramycin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call